What are you looking for?
Faricimab and aflibercept 2 mg produced comparable short-term visual and anatomical outcomes in patients with diabetic macular oedema (DMO), according to a study. The study included 300 patients, with 292 eyes analyzed (191 aflibercept, 101 faricimab). Eyes were treatment-naïve or off therapy for ≥6 months and received a loading phase, with outcomes assessed at four... ...
The U.S. Food and Drug Administration has approved extended dosing intervals for EYLEA HD (aflibercept), allowing treatment up to every 20 weeks...
In another live recording of The Spotlight Series Podcast from the Hawaiian Eye Meeting, host Mario Nacinovich and Judy Kim, MD, of...
A US single-center retrospective study found that socioeconomic status was associated with differences in visual outcomes among patients treated for diabetic macular...
The ranibizumab biosimilar (Vicentis) was noninferior to ranibizumab (Lucentis) for visual acuity (VA) and central subfield thickness (CSFT) in patients with diabetic macular edema, according to a poster presented at...
The challenges that patients with diabetic macular edema (DME) face are often multifactorial, said Randy Wong, MD and Eser Adiguzel, PhD, during a presentation at AAO 2021. “We have to...
APX3330, an oral drug, demonstrated a favorable safety and tolerability profile in the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME), according to data presented from multiple Phase...
Outcomes after injections of either aflibercept or ranibizumab in patients with refractory DME treated initially with bevacizumab injections were similar, according to a study. In this retrospective cohort study, 80...
Patients with diabetic macular edema (DME) who did not adhere to intravitreal aflibercept therapy had significantly worse visual outcomes compared to patients who adhered to treatment, according to a study....
Despite being effective, anti-VEGF therapy has its shortcoming, said the presenters at a CME seminar at Hawaiian Eye and Retina 2021 which examined the current management of diabetic macular edema...
The most common pharmacotherapies for diabetic macular edema (DME) are safe and effective and the current focus is on developing more durable treatments, according to a presentation by Michael S....
Faricimab (Genentech) offered non-inferior vision gains given at intervals of up to 4 months compared to aflibercept given every 2 months in patients with wet age-related macular degeneration (nAMD) or...